Vilon
Synthetic dipeptide bioregulator (Lys-Glu) associated with thymic and geroprotector literature, but supported mainly by small-scale regional and preclinical evidence rather than mainstream therapeutic development.
Vilon is one of the canonical ultrashort peptide bioregulators associated with the Khavinson literature. It is commonly positioned as a thymic / immune / geroprotective peptide and appears in both experimental and small regional clinical contexts, but it has never reached mainstream international drug-development status. The repository should treat Vilon as a niche bioregulator with a real literature footprint, while being very clear that this does not place it in the same evidence tier as approved immune therapeutics.
Vilon is most commonly described as the synthetic dipeptide Lys-Glu, sometimes represented simply as KE. The identity section should also note its relationship to the broader thymic-peptide family and to the historical development arc that includes Thymalin and Thymogen. Because the peptide is short and simple, identity confidence is better than for some bioregulator entries, even if clinical interpretation remains limited.
3. Sequence and structure
Vilon is the dipeptide L-Lys-L-Glu. It is among the simplest entries in the repository from a structural point of view. That simplicity makes it easy to catalog chemically, but it does not solve the harder question of how much biologic or therapeutic specificity can be inferred from the available literature.
The mechanistic narrative centers on chromatin interaction, gene-expression regulation, immune-cell differentiation, anti-apoptotic effects, and other broader cell-regulatory hypotheses rather than on a classic receptor pharmacology story. Some studies also describe antitumor or tissue-protective effects in animal models. These signals are interesting, but the correct repository stance is that mechanism remains hypothesis-rich and clinically under-validated.
Reported or marketed use cases include immune support, aging-related decline, oncologic adjunctive interest, and broad regenerative or resilience themes. These should be labeled as experimental, regional, or low-confidence depending on the source. No mainstream FDA-approved indication exists.
Formal modern ADME characterization is minimal. As with other ultrashort peptides, proposed biologic significance often far exceeds the amount of rigorous PK data available. The database should reflect that gap directly rather than smoothing it over.
The evidence base includes preclinical work, chromatin and apoptosis-related studies, tumor-model observations, and some small regional clinical or translational reports. That is enough to support serious documentation, but not enough to justify high-confidence therapeutic claims. Vilon should therefore be rated as biologically interesting with limited clinical validation.
Public safety information is limited by the scale and nature of the literature. No major modern global safety package was identified, and product-source variability further limits confidence. As with many short bioregulators, benign marketing tone should not be mistaken for fully characterized safety.
No globally standardized approved regimen exists. Reported use spans oral and injectable contexts in different publications and commercial settings, but dosing should only be stored as source-linked and non-approved. The repository should avoid presenting a single canonical human schedule.
UNVERIFIED RESEARCHER-REPORTED DOSING INFORMATION
The following dosing information has been compiled from community forums, researcher discussions, and gray-market sources. This information has NOT been verified through peer-reviewed scientific studies or clinical trials. It does NOT constitute medical advice, a prescription, or a recommendation for human use.
This data is presented solely for informational and educational purposes to document what is commonly discussed in research communities. Dosing protocols may be inaccurate, dangerous, or based on anecdotal reports with no scientific validation. Individual responses vary significantly, and unregulated compounds carry inherent risks including contamination, mislabeling, and unknown side effects.
Always consult qualified medical professionals before making any health-related decisions. The repository maintainers assume no liability for the use or misuse of this information.
Researcher-Reported Dosing Protocols
Common Dose Range: 67-670 mcg per injection
Administration Route: Subcutaneous injection
Frequency: Once daily
Timing: Any consistent time of day.
Schedule / Protocol: 5 consecutive days on, followed by a rest period for the remainder of a 4-week cycle, repeated monthly.
Dose Escalation: It is common to start with a lower dose of 67 mcg on the first day and gradually increase the dosage by approximately 67 mcg each day during the initial cycle, with a target dose of 333-667 mcg daily for subsequent cycles.
Additional Notes: To minimize local irritation, it is recommended to rotate injection sites.
This researcher-reported dosing information was compiled from unverified community sources and does not represent validated scientific or medical guidance.
Vilon has a literature presence, but not the kind of formal modern clinical-trial program that would support a high-maturity therapeutic entry. Most human-facing information comes from small regional or adjunctive-use contexts rather than from multinational registrational development.
Vilon is not FDA approved and does not hold mainstream Western regulatory status. It should be categorized as a niche peptide bioregulator with low regulatory maturity and a primarily regional / experimental evidence base.
13. References and source quality
Highest-value sources include PubMed-indexed studies on Vilon's chromatin, apoptosis, and tumor-model effects, plus broader reviews of peptide bioregulators and thymic peptide derivatives. Source quality is modest and often geographically concentrated, so conservative interpretation is necessary.
Vilon is a simple synthetic dipeptide, which makes manufacturing conceptually straightforward. However, because the commercial ecosystem is not standardized like a major approved drug market, sequence confirmation, purity testing, and product-form transparency still matter. The entry should not assume equivalence across vendors or supplement-style products.
Version 0.1 starter entry created March 14, 2026. Evidence basis for this draft: PubMed-indexed Vilon studies, peptide-bioregulator reviews, and structural identity references confirming Lys-Glu. Recommended future upgrade: add stronger source-specific separation between preclinical and human-use claims.
Next-step recommendation
This document now covers the full initial peptide list supplied for the starter repository. Use it as the master file, append future peptide additions in sequence after entry 077, and keep sections 3 and 13 as the default structure unless a future batch requires a deliberate exception.
Updated on March 14, 2026.